TITLE

FDA's Consideration of Evidence from Certain Clinical Trials

AUTHOR(S)
Crosse, Marcia
PUB. DATE
August 2010
SOURCE
GAO Reports;8/30/2010, preceding p1
SOURCE TYPE
Government Documents
DOC. TYPE
Article
ABSTRACT
The article discusses a study conducted by the U.S. Government Accountability Office (GAO) on the Food and Drug Administration's (FDA's) decision for drug approval. The GAO examined the FDA's use of non-inferiority trial evidence to assess drug effectiveness by looking at new drug applications (NDAs), characteristics of trials, and the FDA's guidance on trials. The GAO found that the FDA has become more conservative in allowing evidence from such trials to demonstrate a drug's effectiveness.
ACCESSION #
53752972

 

Related Articles

  • Noninferiority Trials. Mitka, Mike // JAMA: Journal of the American Medical Association;10/13/2010, Vol. 304 Issue 14, p1546 

    The article focuses on a report by the U.S. Government Accountability Office (GAO) that the U.S. Food and Drug Association (FDA) is doing a better job of appropriately weighing the evidence from noninferiority trials when considering approval of a new drug.

  • FDA Approvals In December.  // BioWorld Insight;1/24/2011, Vol. 19 Issue 4, p6 

    A chart is presented that lists the drugs approved by the U.S. Food and Drug Administration (FDA) in December 2010, Cubicin from Cubist Pharmaceuticals Inc. and Fortesta from Endo Pharmaceuticals Inc.

  • FDA Has Met Most Performance Goals for Reviewing Applications.  // GAO Reports;4/30/2012, preceding p1 

    The article offers information on a report prepared by the U.S. Government Accountability Office related to the performance goals achieved by the U.S. Food and Drug Administration (FDA) during the 2000-2010 fiscal year. It states that the FDA achieved its goal by the completion of the reviews...

  • GAO study of device approvals to take center stage at hearing. McCARTY, MARK // Medical Device Daily;4/14/2011, Vol. 15 Issue 72, p1 

    The article reports on a story featured on the online edition of the "New York Times" newspaper on April 12, 2011 which indicated that a report by the U.S. Government Accountability Office (GAO) will criticize the device approval process of the Food and Drug Administration (FDA). The question of...

  • Accelerated Program Still Too Slow.  // Pharmaceutical Representative;Dec2009, Vol. 39 Issue 12, p11 

    The article presents a report released by the U.S. Government Accountability Office (GAO) on the U.S. Food and Drug Administration's (FDA) slow action plan and approval process of reviewing postmarket trials of drugs. The GAO examines 90 applications from 1992-2008 in which only 64 have been...

  • Critical comparisons.  // Nature Medicine;Oct2010, Vol. 16 Issue 10, p1049 

    The author reflects on the U.S. Food and Drug Administration's (FDAs) use of noninferiority trials in investigating new drugs and its stance on the approval process for generic biologics. The author discusses the guidelines issued by the FDA in March 2010 on the use of noninferiority trials by...

  • GAO: FDA Is Unaware Of Own Budget Needs.  // Chain Drug Review;8/3/2009, Vol. 31 Issue 13, p50 

    The article reports on the statement made by the Government Accountability Office (GOA) that the U.S. Food and Drug Administration (FDA) lacks the means to predict its own budget requirements. GAO argues that FDA does not have the data to develop a complete and reliable estimate of the resources...

  • GAO: FDA's Mifeprex approval 'consistent'. J. G. D. // Medical Marketing & Media;Oct2008, Vol. 43 Issue 10, p14 

    The article cites a report from the Government Accountability Office (GAO) concerning the U.S. Food and Drug Administration's (FDA) approval process for Mifeprex pill. The report states that critics have questioned aspects of the approval process, including the reliance on historically...

  • GAO Report Says FDA Fails on Accelerated Approval Follow-up. Young, Donna // BioWorld Today;10/27/2009, Vol. 20 Issue 207, p1 

    The article discusses a report from the U.S. Government Accountability Office (GAO) in October 2009 concerning the failure of the Food and Drug Administration (FDA) to exercise its authority to recall the drugs that were approved under the accelerated approval process. Example cited by GAO to...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics